ArticleJournal of nanobiotechnology2021
Mitochondria-targeting graphene oxide nanocomposites for fluorescence imaging-guided synergistic phototherapy of drug-resistant osteosarcoma.
Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 68 citations in OpenAlex.
- Exploring the Biocompatibility and Therapeutic Potential of Graphene Oxide-Based Nanomaterials in Modern Medicine. A Comprehensive Review.Applied biochemistry and biotechnology · 2026Review
- Recent Advances in Mitochondria-Targeted Nano-Drug Delivery Systems for Cancer Therapy.International journal of nanomedicine · 2026Review
- Mitochondria and tumorigenesis: Molecular basis and therapeutic implications.Genes & diseases · 2026Review
- Overcoming barriers in primary bone cancer: Nanomaterial-enabled immunotherapy.Materials today. Bio · 2025Review
- Tumor cells targetable graphene oxide doped microneedle for synergistic photothermal-chemotherapy treatment of melanoma.Journal of pharmaceutical analysis · 2025Article
- Two-dimensional nanomaterials for bone disease therapy: multifunctional platforms for regeneration, anti-infection and tumor ablation.Journal of nanobiotechnology · 2025Review
- Graphene Nanocomposites in the Targeting Tumor Microenvironment: Recent Advances in TME Reprogramming.International journal of molecular sciences · 2025Review
- Nanotechnology-Driven Strategies in Osteosarcoma Advances in Treatment: Immunotherapy and Drug Delivery.International journal of nanomedicine · 2025Review
- Nanoparticles and bone microenvironment: a comprehensive review for malignant bone tumor diagnosis and treatment.Molecular cancer · 2024Review
- Current advance of nanotechnology in diagnosis and treatment for malignant tumors.Signal transduction and targeted therapy · 2024Review
- Strategic disruption of cancer's powerhouse: precise nanomedicine targeting of mitochondrial metabolism.Journal of nanobiotechnology · 2024Review
- Advancements in Photothermal Therapy Using Near-Infrared Light for Bone Tumors.International journal of molecular sciences · 2024Review
- The generation and use of animal models of osteosarcoma in cancer research.Genes & diseases · 2024Review
- Graphene Oxide (GO) for the Treatment of Bone Cancer: A Systematic Review and Bibliometric Analysis.Nanomaterials (Basel, Switzerland) · 2024Review
- Comprehensive Assessment of Graphene Oxide Nanoparticles: Effects on Liver Enzymes and Cardiovascular System in Animal Models and Skeletal Muscle Cells.Nanomaterials (Basel, Switzerland) · 2024Article
- Organelle Targeted Drug Delivery: Key Challenges, Recent Advancements and Therapeutic Implications.Endocrine, metabolic & immune disorders drug targets · 2024Review
- Application Research Progress of Nanomaterial Graphene and its Derivative Complexes in Tumor Diagnosis and Therapy.Current medicinal chemistry · 2024Review
- Mild photothermal therapy assist in promoting bone repair: Related mechanism and materials.Materials today. Bio · 2023Review
- Application of advanced biomaterials in photothermal therapy for malignant bone tumors.Biomaterials research · 2023Review
- Exploring the Potential of Nanotechnology in Pediatric Healthcare: Advances, Challenges, and Future Directions.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundOsteosarcoma (OS) is the most common primary malignant bone tumor occurring in children and young adults. Drug-resistant osteosarcoma often results in chemotherapy failure. Therefore, new treatments aimed at novel therapeutic targets are urgently needed for the treatment of drug-resistant osteosarcoma. Mitochondria-targeted phototherapy, i.e., synergistic photodynamic/photothermal therapy, has emerged as a highly promising strategy for treating drug-resistant tumors. This study proposed a new nano-drug delivery system based on near-infrared imaging and multifunctional graphene, which can target mitochondria and show synergistic phototherapy, with preferential accumulation in tumors. METHODS AND
resultsBased on our previous study, (4-carboxybutyl) triphenyl phosphonium bromide (TPP), a mitochondria-targeting ligand, was conjugated to indocyanine green (ICG)-loaded, polyethylenimine-modified PEGylated nanographene oxide sheets (TPP-PPG@ICG) to promote mitochondrial accumulation after cellular internalization. Thereafter, exposure to a single dose of near-infrared irradiation enabled synergistic photodynamic and photothermal therapy, which simultaneously inhibited adenosine triphosphate synthesis and mitochondrial function. Induction of intrinsic apoptosis assisted in surmounting drug resistance and caused tumor cell death. After fluorescence imaging-guided synergistic phototherapy, the mitochondria-targeting, multifunctional graphene-based, drug-delivery system showed highly selective anticancer efficiency in vitro and in vivo, resulting in marked inhibition of tumor progression without noticeable toxicity in mice bearing doxorubicin-resistant MG63 tumor cells.
conclusionThe mitochondria-targeting TPP-PPG@ICG nanocomposite constitutes a new class of nanomedicine for fluorescence imaging-guided synergistic phototherapy and shows promise for treating drug-resistant osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.